Liposomal amphotericin B for the treatment of visceral leishmaniasis

Clinical Infectious Diseases

Volumn 43, Issue 7, 2006, Pages 917-924

  Bern, Caryn ^a   Adler Moore, Jill ^b   Berenguer, Juan ^c   Boelaert, Marleen ^e   Den Boer, Margriet ^f   Davidson, Robert N ^g   Figueras, Concepcion ^d   Gradoni, Luigi ^h   Kafetzis, Dimitris A ^j   Ritmeijer, Koert ^f   Rosenthal, Eric ^k   Royce, Catherine ^l   Russo, Rosario ⁱ   Sundar, Shyam ^m   Alvar, Jorge ^l  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g NORTHWICK PARK HOSPITAL   (United Kingdom)

^h ISTITUTO SUPERIORE DI SANITÀ   (Italy)

ⁱ Istituto Malattie Infettive   (Italy)

^j Aglaia Kyriakou Children's Hospital   (Greece)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m BANARAS HINDU UNIVERSITY   (India)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY; ANTIRETROVIRUS AGENT; MILTEFOSINE; PAROMOMYCIN; AMPHOTERICIN B; ANTIPROTOZOAL AGENT; DRUG CARRIER; LIPOSOME;

BACKACHE; CHILL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; FEVER; HEALTH CARE ACCESS; HEART ARRHYTHMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INFECTION CONTROL; KIDNEY DYSFUNCTION; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESPIRATORY DISTRESS; REVIEW; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS; VOMITING; WORLD HEALTH ORGANIZATION; AIDS RELATED COMPLEX; ANIMAL; ARTICLE; ECONOMICS; HEALTH CARE PLANNING; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS; DRUG CARRIERS; DRUG COSTS; HEALTH PLANNING GUIDELINES; HUMANS; LEISHMANIASIS, VISCERAL; LIPOSOMES; TREATMENT OUTCOME;

EID: 33748647413     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/507530     Document Type: Review

References (43)

1. World Health Organization. Leishmaniasis disease burden. Available at: http://www.who.int/leishmaniasis/burden/en/. Accessed 27 April 2005.
2. Pearson RD, Jeronimo SMB, de Queiroz Sousa A. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone, 1999:797-813.
3. Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 2005; 11:655-62.
4. Addy M, Nandy A. Ten years of kala-azar in west Bengal, part 1: did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 1992; 70:341-6.
5. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
6. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
7. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928-34.
8. Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003; 97:350-4.
9. Anoopa Sharma D, Bern C, Varghese B, et al. The economic impact of visceral leishmaniasis on households in Bangladesh. Trop Med Int Health 2006; 11:757-64.
10. National Vector Borne Disease Control Programme. Drug policy under kala-azar elimination programme as per recommendations of expert committee. 2000. Available at: http://www.namp.gov.in/ka18.html. Accessed 28 June 2005.
11. Seaman J, Boer C, Wilkinson R, et al. Liposomal aniphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21:188-93.
12. Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 2003; 9:1617-20.
13. Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005; 25:26-30.
14. Rosenthal E, Tempesta S, Del Giudice P, et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS 2001; 15:1184-5.
15. del Giudice P, Mary-Krause M, Pradier C, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002; 186:1366-70.
16. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97(Suppl 1):135-42.
17. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000; 14:2946-8.
18. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4:179-85.
19. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45:3487-96.
20. Freire M, Badaro F, Avelar ME, et al. Efficacy and tolerability of liposomal amphotericin B (Ambisome) in the treatment of visceral leishmaniasis in Brazil. Braz J Infect Dis 1997; 1:230-40.
21. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25-32.
22. Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36:560-6.
23. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87:75-81.
24. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938-43.
25. di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131:271-7.
26. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90:319-22.
27. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001; 17:67-70.
28. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323:419-22.
29. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143-6.
30. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37:800-4.
31. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38:377-83.
32. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49(Suppl 1):37-41.
33. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612-9.
34. Meyerhoff A. US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28:42-8; discussion 49-51.
35. Torre-Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17:625-7.
36. Lazanas MC, Tsekes GA, Papandreou S, et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7:1018-9.
37. Laguna F, Torre-Cisneros J, Moreno V, Villanueva JL, Valencia E. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:711-2.
38. Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32:133-7.
39. Montana M, Chochoi N, Monges P, et al. Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases [in French]. Pathol Biol (Paris) 2004; 52:66-75.
40. Laguna F, Videla S, Jimenez-Mejias ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003; 52:464-8.
41. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540-3.
42. Casado JL, Lopez-Velez R, Pintado V, Quereda C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20:202-5.
43. Mira JA, Corzo JE, Rivero A, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70:298-301.